Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single‐dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers
Adele Hosseini, Andrew J. McLachlan, Jason D. Lickliter
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 4, pp. 2070-2077
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain
Barbara Stella, Francesca Baratta, Carlo Della Pepa, et al.
Drugs (2021) Vol. 81, Iss. 13, pp. 1513-1557
Open Access | Times Cited: 99
Cannabidiol‐associated hepatotoxicity: A systematic review and meta‐analysis
Lindsay A. Lo, April Christiansen, Lauren Eadie, et al.
Journal of Internal Medicine (2023) Vol. 293, Iss. 6, pp. 724-752
Open Access | Times Cited: 35
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
Grace Tsz Yan Yau, Waiting Tai, Jonathon C. Arnold, et al.
Pharmaceutical Research (2023) Vol. 40, Iss. 5, pp. 1087-1114
Open Access | Times Cited: 27
Strategies to Improve Cannabidiol Bioavailability and Drug Delivery
Saoirse E. O’Sullivan, Sanne Jensen, Aditya Reddy Kolli, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 244-244
Open Access | Times Cited: 8
A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders
Oluwadara Pelumi Omotayo, Yolandy Lemmer, Shayne Mason
Journal of Cannabis Research (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 6
Comparison of Five Oral Cannabidiol Preparations in Adult Humans: Pharmacokinetics, Body Composition, and Heart Rate Variability
Natasha Williams, Taylor Russell Ewell, Kieran Shay Struebin Abbotts, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 1, pp. 35-35
Open Access | Times Cited: 37
Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review
Graziella Madeo, Ashita Kapoor, Raffaele Giorgetti, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 11, pp. 2323-2342
Open Access | Times Cited: 14
Cannabidiol and its application in the treatment of oral diseases: therapeutic potentials, routes of administration and prospects
Zonghao Hu, Zishun Qin, Jinhong Xie, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116271-116271
Open Access | Times Cited: 4
Oral cannabidiol did not impair learning and memory in healthy adults
Hanna H. Gebregzi, Joanna S. Zeiger, Jeffrey P. Smith, et al.
Journal of Cannabis Research (2025) Vol. 7, Iss. 1
Open Access
Pharmacokinetics of Non-Psychotropic Phytocannabinoids
Mariana Lacerda, Andreia Carona, Sara Castanheira, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 236-236
Open Access
Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Daphnée Brazeau, Amelie A Deshaies, David Williamson, et al.
BMJ Open (2025) Vol. 15, Iss. 2, pp. e092919-e092919
Open Access
Cannabidiol/tetrahydrocannabinol-enrich extract decreases neuroinfalmmation and improves locomotor outcome following spinal cord injury
Julián Del Core, Ignacio Jure, Fresia Melina Silva Sofrás, et al.
Neuroscience (2025)
Closed Access
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool
C. Kwee, Joop MA van Gerven, Fleur L.P. Bongaerts, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 12, pp. 1299-1314
Open Access | Times Cited: 17
Cannabidiol Compared to Pharmacological Treatment as Usual for Crack Use Disorder: A Feasibility, Preliminary Efficacy, Parallel, Double-Blind, Randomized Clinical Trial
Andréa Donatti Gallassi, André Wagner Carvalho de Oliveira, Larissa Alencar Rodrigues, et al.
International Journal of Mental Health and Addiction (2024)
Open Access | Times Cited: 2
3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract
Anna Gościniak, Filip Kocaj, Anna Stasiłowicz-Krzemień, et al.
Gels (2024) Vol. 10, Iss. 12, pp. 770-770
Open Access | Times Cited: 2
A pilot safety, tolerability and pharmacokinetic study of an oro-buccal administered cannabidiol-dominant anti-inflammatory formulation in healthy individuals: a randomized placebo-controlled single-blinded study
Luis Vitetta, Belinda Butcher, Jeremy D. Henson, et al.
Inflammopharmacology (2021) Vol. 29, Iss. 5, pp. 1361-1370
Closed Access | Times Cited: 13
The effects of cannabidiol on subjective states, cognition, and psychomotor function in healthy adults: A randomized clinical trial
Toni Marie Rudisill, Kim E. Innes, Sijin Wen, et al.
Fundamental and Clinical Pharmacology (2023) Vol. 37, Iss. 3, pp. 663-672
Open Access | Times Cited: 5
Cannabidiol safety considerations: Development of a potential acceptable daily intake value and recommended upper intake limits for dietary supplement use
Rayetta G. Henderson, Melissa Vincent, Brianna N. Rivera, et al.
Regulatory Toxicology and Pharmacology (2023) Vol. 144, pp. 105482-105482
Open Access | Times Cited: 5
Pharmacokinetics of Cannabidiol: A Systematic Review and Meta-Regression Analysis
Ehsan Moazen‐Zadeh, Alexandra Chisholm, Keren Bachi, et al.
Cannabis and Cannabinoid Research (2023) Vol. 9, Iss. 4, pp. 939-966
Open Access | Times Cited: 5
Pharmacokinetics of Cannabidiol: A systematic review and meta-regression analysis
Ehsan Moazen‐Zadeh, Alexandra Chisholm, Keren Bachi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Measuring the diversity gap of cannabis clinical trial participants compared to people who report using cannabis
Heather M. Barkholtz, M Bates
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
Cannabidiol - Help and hype in targeting mucosal diseases
Md. Moniruzzaman, Taskeen Iqbal Janjua, Jennifer Martin, et al.
Journal of Controlled Release (2023) Vol. 365, pp. 530-543
Open Access | Times Cited: 4
Determination of Δ9-tetrahydrocannabinol, 11-nor-carboxy-Δ9-tetrahydrocannabinol and cannabidiol in human plasma and urine after a commercial cannabidiol oil product intake
Ioannis Papoutsis, Vasiliki Hatzidouka, Stamatina-Panagoula Ntoupa, et al.
Forensic Toxicology (2024) Vol. 42, Iss. 2, pp. 191-201
Open Access | Times Cited: 1
Clinical guidance for cannabidiol‐associated hepatotoxicity: A narrative review
Lauren Eadie, Lindsay A. Lo, Michael Boivin, et al.
Journal of Gastroenterology and Hepatology (2024)
Open Access | Times Cited: 1
The Effectiveness and Safety of Cannabidiol in Non-seizure-related Indications: A Systematic Review of Published Randomized Clinical Trials
Yuni Tang, Kolbi L. Tonkovich, Toni Marie Rudisill
Pharmaceutical Medicine (2022) Vol. 36, Iss. 6, pp. 353-385
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top